![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
References
- BNF (British National Formulary). 2008. Appendix 4: 807. 56th edn. London; BMJ Group and RPS Publishing.
- Cervantes FJ, Alvarez-Larran A, Domingo A et al. 2005. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. British Journal of Haematology 129:771–775.
- Heal JM, Blumberg N. 2004. Optimizing platelet transfusion therapy. Blood Reviews 18:149–165.
- Herbar M, Kaplan C, Caulier MT et al. 1996. Low incidence of specific anti-platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy. British Journal of Haematology 94:112–115.
- Lionne-Huyghe P, Kuhnowski F, Coiteux V et al. 2006. Indications of G-CSF administration in hematologic disorders. Bulletin of Cancer 93:453–462.
- Marsh JC, Ball SE, Cavenagh J et al. 2009. Guidelines for the diagnosis and management of aplastic anaemia. British Journal of Haematology 147:43–70.
- Rebulla P. 2000. Trigger for platelet transfusion. Vox Sanguinis 78:S179–S182.
- Rosenfeld S, Follmann D, Nunez O et al. 2003. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. Journal of the American Medical Association 289:1130–1135.
- Sniecinski I, O'Donnell MR, Nowicki B et al. 1988. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 71:1402–1407.
- Storb R. 1997. Aplastic anemia. Journal of Intravenous Nursing 20:317–322.
- Young NS, Scheinberg P, Calado RT. 2008. Aplastic anaemia. Current Opinions in Internal Medicine 7:338–344.